Pradeep Singh, MD
Family Practice · Lancaster, CANPI 1891737656
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $544 of the $624 with a category attached, or 87.2%. It is spread thinly across 13 manufacturers, the largest accounting for just 22.5% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $202 and has fallen 72.4% since, to $56 in 2024. Among family practice clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 28 payments — averaging $22.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$140
- AstraZeneca$120
- Astellas Pharma US Inc$118
- Novartis$59
- GSK$56
- Boehringer Ingelheim$27
- plus $105 from 7 others
What the payments were for
- Food & beverage$54487%
- Education$8013%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 9 | $140 |
| AstraZeneca | 3 | $120 |
| Astellas Pharma US Inc | 1 | $118 |
| Novartis | 3 | $59 |
| GSK | 3 | $56 |
| Boehringer Ingelheim | 2 | $27 |
| Pfizer | 1 | $19 |
| Merck | 1 | $18 |
| Avanir Pharmaceuticals, Inc. | 1 | $16 |
| Circassia Inc. | 1 | $14 |
| Dexcom, Inc. | 1 | $14 |
| AbbVie | 1 | $12 |
| Mylan Specialty L.p. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Veozah$118
How this compares
$624 in reported general payments places this provider in the 95th percentile of 2,195 family practice providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Atrovent HfaIpratropium Bromide | 301 | $177,380 |
| JardianceEmpagliflozin | 165 | $122,787 |
| FarxigaDapagliflozin Propanediol | 120 | $70,691 |
| OzempicSemaglutide | 69 | $67,923 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 84 | $56,412 |
| EliquisApixaban | 86 | $47,441 |
| Spiriva RespimatTiotropium Bromide | 80 | $39,598 |
| TradjentaLinagliptin | 50 | $36,459 |
| JanuviaSitagliptin Phosphate | 49 | $32,927 |
| GlyxambiEmpagliflozin/Linagliptin | 21 | $18,960 |
| XareltoRivaroxaban | 23 | $17,934 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 16 | $16,768 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 44 | $14,159 |
| RybelsusSemaglutide | 14 | $13,117 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,936 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Spiriva Respimat, Tradjenta, Glyxambi | $27 | $217,804316 claims |
| Novo NordiskOzempic, Rybelsus | $140 | $81,04183 claims |
| AstraZenecaFarxiga, Brilinta | $120 | $77,554134 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $56 | $66,348103 claims |
| PfizerEliquis | $19 | $47,44186 claims |
| MerckJanuvia | $18 | $32,92749 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,195 family practice providers in California.
Other family practice in Lancaster
- David CahnSan Jose$40K
- Linh NguyenSan Jose$15K
- Paige YoshisatoVallejo$14K
- Boris VaismanWoodland Hills$11K
- Sharon LaughlinRiverside$8K
- Michael KanLos Gatos$4K
- Claudia CarranzaBakersfield$4K
- Sunil HebbarHermosa Beach$3K
- Monica SuNewbury Park$3K
- Taraneh MatinPasadena$3K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.